Virtual reality surgical training wins industry attention with scalable model

Tern plc

A virtual reality training platform developed by Fundamental XR and Orbis International has been awarded Gold in a major technology competition, highlighting how immersive tools are starting to gain traction in global medical education.

This programme, focused on ophthalmic surgery, allows medical trainees to practise procedures in a fully immersive virtual environment, without the limitations of physical equipment, live supervision or real-world patient risk. The result is a more accessible, standardised form of surgical education, especially valuable in countries where hospital training resources are limited or overstretched.

What sets this initiative apart is its focus on real-world application. The technology has been designed to fit the workflow and constraints of medical education systems in lower-resource settings. This combination of technical quality and real-world relevance is what earned the recognition, and it signals a step forward for VR in professional training markets.

Orbis brings decades of experience in eye care and surgical training around the world, while Fundamental XR provides the technical capability to deliver high-fidelity, scalable simulations. Together, they have built a tool that solves a pressing educational problem with modern technology, a clear use case with long-term potential.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Tern Plc announces 90% take-up of Open Offer

Tern Plc has received valid acceptances for 50.9 million Open Offer Shares, representing approximately 90% of the shares available. The fully underwritten offer will raise approximately £509,368 before expenses, with admission of the new shares expected on 24 September 2026.

Talking Medicines moves to capture pharma demand for better patient intelligence

Tighter US pharma advertising rules could increase demand for patient intelligence, supporting the relevance of Talking Medicines’ DrugVoice platform.

Tern portfolio company Talking Medicines launches ‘Intent to Prescribe’ DrugVoice application

Talking Medicines has launched a new DrugVoice application combining its Message Resonance Score™ with near-real-time point-of-care data to help pharmaceutical companies assess links between HCP message alignment and prescribing intent.

Search